Our research infrastructure
More…
More…
More…
More…
Our long-term investment in state-of-the-art facilities has helped to create a thriving network of research at 90 institutions in more than 40 towns and cities across the UK.
At CRUK we recognise the crucial role that infrastructure plays in creating a dynamic and responsive research environment. Our infrastructure provides capabilities across the full breadth of cancer research and the translational pipeline, from basic biology research through to the delivery of late-phase clinical trials, and supports close partnerships with universities and the NHS.
Explore our capabilities below, or view our facilities by geographical location
Our four core-funded research institutes provide an exceptional environment for discovery science, and have an outstanding track record including four Nobel Prize winners. More than a third of our research spend goes to our institutes, funding over 120 research groups across the breadth of cancer science, supported by state-of-the-art facilities.
Alongside the CRUK Beatson Institute in Glasgow, the CRUK Cambridge Institute and the CRUK Manchester Institute, we’re partners in the multidisciplinary Francis Crick Institute in London – Europe’s largest single-location biomedical research institute.
Our network of 14 translational research centres drives local collaborations between universities, NHS hospitals, and other research organisations. Together, they operate as a network which plays a key role in delivering our strategic objectives in translational research, with different Centres contributing their expertise in different tumour sites and research themes.
We award Centre status to locations performing the highest quality cancer research, and we provide over £200 million of infrastructure investment funding across the network for technical staff, equipment, training and running costs, developing the breadth and depth of research at each of these Centres.
We have a network of four small-molecule academic Drug Discovery Units, including the world’s largest and leading academic drug discovery group at The Institute of Cancer Research. We also have in-house Therapeutic Discovery Labs.
This innovative collaboration with AstraZeneca’s global biologics arm is accelerating the translation of cancer research into potential new bio-therapeutic drugs. The alliance gives researchers access to MedImmune’s capabilities and technology.
Our four Cancer Imaging Centres drive progress in multidisciplinary research which impacts the detection, diagnosis and treatment of cancer. The centres are an integral resource for our translational research, accelerating new diagnostics and therapeutics.
Our network of 18 Experimental Cancer Medicine Centres (ECMCs) provides a unique service for early phase trials, not only for treatments we develop and optimise ourselves, but also for trials from industry and other funders.
We support eight Clinical Trials Units which provide the academic cancer research community with expertise to design and run trials at all phases. They coordinate national and international trials, and other studies which directly influence routine clinical practice.
Our 15 senior research nurses facilitate the delivery of clinical research in the NHS across the UK, working closely with researchers at our Centres and ECMCs. They support patient recruitment and the involvement of people affected by cancer in research design.
Our Lung Cancer Centre of Excellence unites teams at the University of Manchester and UCL to catalyse imaginative and innovative lung cancer research across basic and translational research, and sets the global agenda for this cancer with substantial unmet need.
In partnership with other agencies, we fund the UK’s outstanding infrastructure for population research, epidemiology and behavioural sciences. We are a part of the UK Clinical Research Collaboration which funds five Public Health Research Centres of Excellence, and we’re building capacity in health informatics research through the Farr Institute.
Our Stratified Medicine Programme is making precision medicine a reality for patients. The programme has established Technology Hubs as part of its pioneering use of Next Generation Sequencing technology for genetic screening in the NHS.
Our Centre for Drug Development (CDD) translates today’s science into tomorrow’s medicine. The CDD is unique as a charity-funded drug development group, with over 100 scientists and operational staff providing full capabilities across pre-clinical and early-phase development.
The CDD is a centre of excellence providing expertise and facilities to the academic research community and also partnering with industry to accelerate early phase drug development.
Explore our network by geographical location and by the type of facilities that we fund.
We’ve recently made some changes to the site and are looking at how best we can help researchers find relevant information and opportunities. If you have any feedback on this page, or if there was something you were looking for but couldn’t find, we’d love to hear from you.
Our research infrastructure
Research & References of Our research infrastructure|A&C Accounting And Tax Services
Source
0 Comments